Ablynx and Merck expand ion channel research collaboration
Belgian drug developer Ablynx (Euronext Brussels: ABLX) has expanded its initial two-year research collaboration with US pharma giant Merck & Co (NYSE: MRK) to develop and commercialize Nanobody candidates directed towards an undisclosed voltage gated ion channel.
Merck will extend its funding of the research collaboration with Ablynx to the end of September 2016. This ion channel collaboration was announced in October 2012 and included a 6.5 million-euro ($7 million) upfront payment and 2 million euros in initial research funding.
Merck and Ablynx have a separate collaboration in the field of cancer immuno-therapy, announced in February in 2014, with a 20 million-euro upfront payment, 10.7 million euros in research funding and total potential milestone payments of up to 1.7 billion euros plus royalties.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze